Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

US Senators support inclusion of 12-year exclusivity period in Trans-Pacific Partnership free trade agreement (Patent Docs) (BIOtechNOW) (FDA Law Blog)

Nexavar (Sorafenib) – India: Anatomy of NATCO’s compulsory license application (Spicy IP) (IIPRD Blog)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Pharma executive to head Gates’ Global Health Program (IP Watch)

Obama Administration wants to eliminate references to Doha Declaration in UN Political Declaration on Non-Communicable Diseases (KEI)

KEI submission to the WIPO Standing Committee on the Law of Patents (SCP): Patents and Health (KEI)

USTR releases new White Paper on Access to Medicine: includes almost no specifics in terms of negotiating positions (KEI)

Cables that mention Novartis (KEI)

Data protection, Trans Pacific Partnership, and the US-Jordan FTA (Post 2 of 2) (BIOtechNOW)

Denmark: Does obtaining an MA pre-expiry of a patent constitute infringement? (Kluwer Patent Blog)

Dominican Republic: December 2009 meeting between PhRMA and US Embassy to discuss CAFTA+ demands on patent protection (KEI)

France gets an A+ from the US for its anti-consumer intellectual property related policies (KEI)

India: The Novartis patent intervention (Spicy IP)

Spain: Revisiting imminence and ‘periculum in mora’ (Kluwer Patent Blog)

Thailand – Patent evergreening in Thailand (IP Komodo)

US Senators support inclusion of 12-year exclusivity period in Trans-Pacific Partnership free trade agreement (Patent Docs) (BIOtechNOW) (FDA Law Blog)

US: What does Classen v. Biogen mean for the patent eligibility of diagnostics and personalized medicine? (Holman’s Biotech IP Blog)

US: Classen v. Biogen – Additional views from Chief Judge Rader (Patent Docs)

US: Classen v. Biogen – Moore dissent (Patent Baristas)

US: Patent Reform Bill passes: medicines company to party like they’re Rebecca Black (Patent Baristas)

US: H.R. 1249 – Patents directed to human organisms (Patently-O)

US: NORD petition requests FDA policy statement on orphan drug review flexibility (FDA Law Blog)

US: FDA issues proposed PDUFA V Performance Goals & Procedures (FDA Law Blog)

US: Mirus Bio files lawsuit alleging that Roche’s FuGENE 6 transfection reagent infringes patent (Holman’s Biotech IP Blog)

US: Brandeis University and licensee GFA Brands file patent infringement suit against healthy-heart cookie makers (Holman’s Biotech IP Blog)

 

Products

Copaxone (Glatiramer) – US: Teva’s patents covering Copaxone upheld in infringement suit (Patent Docs) (IP Factor)

Glivec – (Imatinib) – India: In defence of Justice Dalveer Bhandari (Spicy IP)

Glivec (Imatinib) – India: Full text of the letter asking for Justice Bhandari’s recusal from the Novartis Glivec dispute (Spicy IP)

Intuniv (Guanfacine) – US: Shire avoids dismissal in patent suit over generic Intuniv (Patent Docs)

Lipitor (Atorvastatin) – UK: English High Court orders speedy trial in Lipitor case (Kluwer Patent Blog)

Nexavar (Sorafenib) – India: Anatomy of NATCO’s compulsory license application (Spicy IP) (IIPRD Blog)

Oracea (Doxycycline) – US: Mylan found to infringe one of Galderma’s Oracea patents (Patent Docs)